The yield of tigecycline in the treatment of community-acquired pneumonia;Toplumda gelişen pnömonide tigesiklin kullanımı

Tuberkuloz ve Toraks

Volumn 61, Issue 2, 2013, Pages 155-161

  Çilli, Aykut ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

Author keywords

Community acquired pneumonia; Tigecycline

Indexed keywords

LEVOFLOXACIN; TIGECYCLINE;

COMMUNITY ACQUIRED PNEUMONIA; DRUG EFFICACY; GASTROINTESTINAL DISEASE; HUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

EID: 84880499004     PISSN: 04941373     EISSN: None     Source Type: Journal    
DOI: 10.5578/tt.5032     Document Type: Review

References (39)

1. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163: 1730-54.
2. T.C. Saǧli{dotless}k Bakanli{dotless}ǧi{dotless}, Refik Saydam Hi{dotless}fzi{dotless}ssi{dotless}hha Merkezi Başkanli{dotless}ǧi{dotless} Hi{dotless}fzi{dotless}ssi{dotless}hha Mektebi Müdürlüǧü, Başkent Üniversitesi Ulusal Hastali{dotless}k Yükü ve Maliyeti Etkinlik Projesi, 2004.
3. Özlü T, Bülbül Y, Özsu S. Community-acquired pneumonia with national data. Tuberk Toraks 2007; 55: 191-212.
4. Özlü T, Bülbül Y, Alataş F, Arseven O, Coşkun AŞ, Çilli A, et al. Turkish Thoracic Society Community-Acquired Pneumonia Guideline. Turk Toraks Derg 2009; 10: 3-16.
5. Wyeth Pharmaceuticals. Tygacil (Package Insert). Philadelphia (PA): Wyeth Pharmaceuticals; 2010.
6. Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 2001; 65: 232-60.
7. Speer BS, Shoemaker NB, Salyers AA. Bacterial resistance to tetracycline: mechanisms, transfer, and clinical significance. Clin Microbiol Rev 1992; 5: 387-99.
8. Rasmussen BA, Gluzman Y, Tally FP. Inhibition of protein synthesis occurring on tetracycline-resistant, TetM-protected ribosomes by a novel class of tetracyclines, the glycylcyclines. Antimicrob Agents Chemother 1994; 38: 1658-60.
9. Tally FT, Ellestad GA, Testa RT. Glycylcyclines: a new generation of tetracyclines. J Antimicrob Chemother 1995; 35: 449-52.
10. Zhanel GG, Homenuik K, Nichol K, Noreddin A, Vercaigne L, Embil J, et al. The glycylcyclines: a comparative review with the tetracyclines. Drugs 2004; 64: 63-88.
11. Clinical and Laboratory Standards Institute (CLSI) [formerly National Committee for Clinical Laboratory Standards (NCCLS)]. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That GrowAerobically. 8th ed. Wayne (PA): CLSI; 2009.
12. Clinical and Laboratory Standards Institute (CLSI) [formerly National Committee for Clinical Laboratory Standards (NCCLS)]. Performance Standards for Antimicrobial Susceptibility Testing-19th Informational Supplement. Wayne (PA): CLSI; 2009.
13. Sader HS, Jones RN, Stilwell MG, Dowzicky MJ, Fritsche TR. Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents. Diagn Microbiol Infect Dis 2005; 52: 181-6.
14. Darabi A, Hocquet D, Dowzicky MJ. Antimicrobial activity against Streptococcus pneumoniae and Haemophilus influenzae collected globally between 2004 and 2008 as part of the Tigecycline Evaluation and Surveillance Trial. Diagn Microbiol Infect Dis 2010; 67: 78-86.
15. Garrison MW, Nuemiller JJ. In vitro activity of tigecycline against quinolone-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci. Int J Antimicrob Agents 2007; 29: 191-6.
16. Mendes RE, Sader HS, Deshpande L, Jones RN. Antimicrobial activity of tigecycline against community-acquired methicillin-resistant Staphylococcus aureus isolates recovered from North American medical centers. Diagn Microbiol Infect Dis 2008; 60: 433-6.
17. Zhanel GG, Palatnick L, Nichol KA, Low DE, Hoban DJ; CROSS Study Group. Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob Agents Chemother 2003; 47: 1875-81.
18. Ko KS, Song JH, Lee MY, Park S, Kwon KT, Heo ST, et al. Antimicrobial activity of tigecycline against recent isolates of respiratory pathogens from Asian countries. Diagn Microbiol Infect Dis 2006; 55: 337-41.
19. Waites KB, Duffy LB, Dowzicky MJ. Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial. Antimicrob Agents Chemother 2006; 50: 3479-84.
20. Bradford PA, Weaver-Sands DT, Petersen PJ. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. Clin Infect Dis 2005; 41(Suppl 5): 315-32.
21. Kenny GE, Cartwright FD. Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones. Antimicrob Agents Chemother 2001; 45: 2604-8.
22. Roblin PM, Hammerschlag MR. In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis. Int J Antimicrob Agents 2000; 16: 61-3.
23. Edelstein PH, Weiss WJ, Edelstein MA. Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother 2003; 47: 533-40.
24. Muralidharan G, Micalizzi M, Speth J, Raible D, Troy S. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005; 49: 220-9.
25. Rubino CM, Forrest A, Bhavnani SM, Dukart G, Cooper A, Korth-Bradley J, et al. Tigecycline population pharmacokinetics in patients with community-or hospital acquired pneumonia. Antimicrob Agents Chemother 2010; 54: 5180-6.
26. Conte JE Jr, Golden JA, Kelly MG, Zurlinden E. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int J Antimicrob Agents 2005; 25: 523-9.
27. Gotfried MH, Rodvold KA, Cwik M, Troy SM, Dukart G, Ellis-Grosse EJ. An open-label clinical evaluation of tigecycline concentrations in selected tissues and fluids. Clin Pharmacol Ther 2005; 77(Suppl 2): 98.
28. Sun HK, Ong CT, Umer A, Harper D, Troy S, Nightingale CH, et al. Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations. Antimicrob Agents Chemother 2005; 49: 1629-32.
29. Rodvold KA, Gotfried MH, Cwik M, Korth-Bradley JM, Dukart G, Ellis-Grosse EJ. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother 2006; 58: 1221-9.
30. Scheetz MH, Reddy P, Nicolau DP, Noskin GA, Postelnick MJ, Stosor V, et al. Peritoneal fluid penetration of tigecycline. Ann Pharmacother 2006; 40: 2064-7.
31. Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. Pharmacokinetic/ pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent. Diagn Microbiol Infect Dis 2005; 52: 165-71.
32. Muralidharan G, Fruncillo RJ, Micalizzi M, Raible DG, Troy SM. Effects of age and sex on single-dose pharmacokinetics of tigecycline in healthy subjects. Antimicrob Agents Chemother 2005; 49: 1656-9.
33. Troy SM, Muralidharan G, Micalizzi M, Mojavarian P, Salacinski L, Raible D. The effects of renal disease on the pharmacokinetics of tigecycline (GAR-936). 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy [meeting abstract]; September 14-17, 2003; Chicago, IL.
34. Saunders S, Baird-Bellaire SJ, Patat AA, et al. Pharmacokinetics of tigecycline (TGC) in patients with hepatic impairment. European Association for Clinical Pharmacology and Therapeutics [meeting abstract]; June 24-29, 2005; Poznan, Poland.
35. Garrison MW, Mutters R, Dowzicky MJ. In vitro activity of tigecycline and comparator agents against a global collection of gram-negative and gram-positive organisms: Tigecycline Evaluation and Surveillance Trial 2004 to 2007. Diagn Microbiol Infect Dis 2009; 65: 288-99.
36. Wyeth Pharmaceuticals. Response Letter for Tigecycline Inquiry Regarding Legionella pneumophila in vitro Data (Data on File). Philadelphia (PA): Wyeth Pharmaceuticals; 2010.
37. Bergallo C, Jasovich A, Teglia O, Oliva ME, Lentnek A, de Wouters L, et al.; 308 Study Group. Diagn Microbiol Infect Dis 2009; 63: 52-61. doi:10.1016/j.diagmicrobio.2008.09.001. Epub 2008 Nov 5.
38. Tanaseanu C, Milutinovic S, Calistru PI, Strausz J, Zolubas M, Chernyak V, et al; 313 Study Group. BMC Pulm Med 2009; 9: 44.
39. Tanaseanu C, Bergallo C, Teglia O, Jasovich A, Oliva ME, Dukart G, et al; 308 Study Group; 313 Study Group. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn Microbiol Infect Dis 2008; 61: 329-38.